DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition.
Deepull has raised €93M across 6 funding rounds from 19 investors, most recently a Series C round in Apr 2025. Based in Barcelona, Spain; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-04-29 | Series C | €50M | Aliath Bioventures,Asabys Partners,Axis-Ico,CGHealth Ventures,Columbus Venture Partners,Gesamo+4 more | View deal → |
| 2023-03-02 | Other | €4.0M | Sabadell Asabys | View deal → |
| 2022-12-14 | Debt | €20M | The European Investment Bank (EIB) | View deal → |
| 2022-11-15 | Other | €2.3M | Alta Life Sciences,CDTI,FCR | View deal → |
| 2022-10-20 | Series B | €13M | Alta Life Sciences,Axis Participaciones Empresariales,Innvest,Kurma Partners,UI Investissement | View deal → |
| 2020-07-08 | Series A | €3.5M | Alta Life Sciences,Kurma Partners | View deal → |
